156 related articles for article (PubMed ID: 17172611)
1. Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
Tong J; Hornykiewicz O; Kish SJ
Arch Neurol; 2006 Dec; 63(12):1724-8. PubMed ID: 17172611
[TBL] [Abstract][Full Text] [Related]
2. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
3. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation.
Rajput AH; Sitte HH; Rajput A; Fenton ME; Pifl C; Hornykiewicz O
Neurology; 2008 Apr; 70(16 Pt 2):1403-10. PubMed ID: 18172064
[TBL] [Abstract][Full Text] [Related]
4. Identification of a noradrenaline-rich subdivision of the human nucleus accumbens.
Tong J; Hornykiewicz O; Kish SJ
J Neurochem; 2006 Jan; 96(2):349-54. PubMed ID: 16336226
[TBL] [Abstract][Full Text] [Related]
5. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
Lee CS; Schulzer M; de la Fuente-Fernández R; Mak E; Kuramoto L; Sossi V; Ruth TJ; Calne DB; Stoessl AJ
Arch Neurol; 2004 Dec; 61(12):1920-5. PubMed ID: 15596613
[TBL] [Abstract][Full Text] [Related]
6. Dopamine in thelimbic regions of the human brain: normal and abnormal.
Farley IJ; Price KS; Hornykiewicz O
Adv Biochem Psychopharmacol; 1977; 16():57-64. PubMed ID: 883559
[TBL] [Abstract][Full Text] [Related]
7. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
Mogi M; Kondo T; Mizuno Y; Nagatsu T
Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
[TBL] [Abstract][Full Text] [Related]
8. Norepinephrine: The redheaded stepchild of Parkinson's disease.
Rommelfanger KS; Weinshenker D
Biochem Pharmacol; 2007 Jul; 74(2):177-90. PubMed ID: 17416354
[TBL] [Abstract][Full Text] [Related]
9. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
Orzi F; Fornai F; Blandini F
Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
[No Abstract] [Full Text] [Related]
10. [Microdialysis cerebral. Main application of this technique].
Blanco-Lezcano L; Pavón-Fuentes N; Blanco-Lezcano V
Rev Neurol; 2001 Sep 1-15; 33(5):464-70. PubMed ID: 11727216
[TBL] [Abstract][Full Text] [Related]
11. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
[TBL] [Abstract][Full Text] [Related]
12. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Julien C; Berthiaume L; Hadj-Tahar A; Rajput AH; Bédard PJ; Di Paolo T; Julien P; Calon F
Neurochem Int; 2006 Apr; 48(5):404-14. PubMed ID: 16442670
[TBL] [Abstract][Full Text] [Related]
13. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
15. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Fulceri F; Biagioni F; Ferrucci M; Lazzeri G; Bartalucci A; Galli V; Ruggieri S; Paparelli A; Fornai F
Brain Res; 2007 Mar; 1135(1):219-29. PubMed ID: 17222394
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
17. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
18. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness.
Bird ED; Spokes EG; Iversen LL
Acta Psychiatr Scand Suppl; 1980; 280():63-73. PubMed ID: 6447433
[No Abstract] [Full Text] [Related]
19. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.
de Lago E; Ortega-Gutiérrez S; Ramos JA; López Rodríguez ML; Fernández-Ruiz J
Life Sci; 2007 Feb; 80(10):979-88. PubMed ID: 17173937
[TBL] [Abstract][Full Text] [Related]
20. Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
Righi S; Viggiano MP; Paganini M; Ramat S; Marini P
Neuropsychologia; 2007 Oct; 45(13):2931-41. PubMed ID: 17662314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
